What's Happening?
enGene Therapeutics has released updated interim results from its Phase 2 LEGEND trial, evaluating detalimogene voraplasmid for high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The trial, involving 125 patients, showed a 54% complete
response rate at any time and a 43% response rate at six months. The therapy demonstrated a low progression rate to muscle-invasive disease and was generally well tolerated, with most adverse events being mild. These findings support the potential of detalimogene as a viable treatment option for patients with limited therapeutic alternatives.
Why It's Important?
The results from the LEGEND trial underscore the potential of non-viral gene therapies in treating high-risk NMIBC, a condition with significant unmet medical needs. The favorable safety profile and efficacy of detalimogene could offer a bladder-sparing alternative to cystectomy, improving patient outcomes and quality of life. This development highlights the growing role of gene therapy in oncology, potentially leading to new treatment paradigms for bladder cancer and other malignancies.
What's Next?
enGene plans to continue engaging with the FDA as it approaches a potential Biologics License Application filing. The company will present these findings at the upcoming American Urological Association meeting. Further analysis of the data is ongoing, with a focus on understanding the factors contributing to treatment response and durability.
